LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

45.29 -2.79

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

45.26

Max

45.69

Galvenie mērījumi

By Trading Economics

Ienākumi

34M

22M

Pārdošana

16M

165M

P/E

Sektora vidējais

39.844

35.664

Peļņas marža

13.598

Darbinieki

674

EBITDA

20M

38M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-2.33% downside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

495M

2.6B

Iepriekšējā atvēršanas cena

48.08

Iepriekšējā slēgšanas cena

45.29

Ziņu noskaņojums

By Acuity

12%

88%

13 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. sept. 22:41 UTC

Galvenie tirgus virzītāji

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025. g. 12. sept. 16:04 UTC

Galvenie tirgus virzītāji

Upexi Shares Climb on Solana Gains

2025. g. 12. sept. 15:03 UTC

Galvenie tirgus virzītāji

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

2025. g. 13. sept. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 20:09 UTC

Peļņas

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025. g. 12. sept. 19:23 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:16 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:03 UTC

Tirgus saruna

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025. g. 12. sept. 18:59 UTC

Tirgus saruna

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025. g. 12. sept. 18:38 UTC

Tirgus saruna
Peļņas

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025. g. 12. sept. 18:33 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025. g. 12. sept. 18:22 UTC

Tirgus saruna

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025. g. 12. sept. 16:56 UTC

Tirgus saruna

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025. g. 12. sept. 16:22 UTC

Peļņas

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025. g. 12. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 12. sept. 16:11 UTC

Peļņas

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025. g. 12. sept. 15:37 UTC

Tirgus saruna

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025. g. 12. sept. 15:22 UTC

Tirgus saruna

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025. g. 12. sept. 15:07 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 14:34 UTC

Tirgus saruna

Russia Sanctions Put Bid Back in Oil -- Market Talk

2025. g. 12. sept. 14:10 UTC

Tirgus saruna

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

2025. g. 12. sept. 13:58 UTC

Tirgus saruna

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

2025. g. 12. sept. 13:58 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 13:57 UTC

Peļņas

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

2025. g. 12. sept. 13:56 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 12. sept. 13:56 UTC

Tirgus saruna

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

-2.33% uz leju

Prognoze 12 mēnešiem

Vidējais 44.4 USD  -2.33%

Augstākais 52 USD

Zemākais 40 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

3

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Neutral Evidence

Noskaņojums

By Acuity

13 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat